In irradiated tumor cells, DNA-PK inhibitors did not induce type I IFN signaling through the classical cGAS/STING signaling pathway, but in a manner dependent on RNA polymerase III (POL III), retinoic acid-inducible gene I (RIG-I), and antiviral signaling protein (MAVS), while also promoting the expression of PD-L1, reversing the poor immunogenicity of tumor cells and increasing sensitivity to anti-PD-L1 antibodies (Wang et al., 2022). The gene discussed is PRKDC; the disease is neoplasm.